ARGENICA THERAPEUTICS LIMITED - Announcements

Market Cap $106.3M Add to my watchlist

Healthcare

Argenica Therapeutics Limited is an Australia-based clinical drug development company.... Argenica Therapeutics Limited is an Australia-based clinical drug development company. The Company is focused on developing therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead candidate, ARG-007, is a cationic arginine-rich peptide that aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimize the impact of these conditions and improve patient recovery. ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

AGN	Notice of Annual General Meeting/Proxy Form		21/10/22	627.57KB	Share
AGN	Investor Presentation		20/10/22	2.7MB	Share
AGN	First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007	PRICE SENSITIVE	17/10/22	190.48KB	Share
AGN	Argenica Receives $1.38m R&D Tax Incentive Cash Refund	PRICE SENSITIVE	04/10/22	171.67KB	Share
AGN	Further Positive Preclinical Results for ARG-007 In HIE	PRICE SENSITIVE	29/09/22	486.34KB	Share
AGN	Date of AGM and Closing Date for Director Nominations		16/09/22	186.81KB	Share
AGN	Phase 1 Clinical Trial Summary		08/09/22	202.58KB	Share
AGN	Argenica Receives Ethics Approval To Commence Phase 1 Trial	PRICE SENSITIVE	07/09/22	229.38KB	Share
AGN	Appendix 4G & Corporate Governance Statement		23/08/22	508.22KB	Share
AGN	Appendix 4E & Annual Report 30 June 2022	PRICE SENSITIVE	23/08/22	1.31MB	Share
AGN	Ethics Application Submitted for Phase 1 Trial		11/08/22	218.25KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	453.67KB	Share
AGN	Clinical Advisory Committee Appointment		11/07/22	190.38KB	Share
AGN	Notification regarding unquoted securities - AGN		11/07/22	28.11KB	Share
AGN	Peer Reviewed Paper Published on Preclinical Safety Study	PRICE SENSITIVE	07/07/22	212.52KB	Share
AGN	Investor Presentation - Updated		17/06/22	3.41MB	Share
AGN	Change of Director's Interest Notice x2		16/06/22	313.37KB	Share
AGN	Investor Presentation		14/06/22	3.34MB	Share
AGN	Notification regarding unquoted securities - AGN		10/06/22	383.34KB	Share
AGN	Cleansing Notice		10/06/22	172.3KB	Share
AGN	Application for quotation of securities - AGN		10/06/22	24.82KB	Share
AGN	Proposed issue of securities - AGN		03/06/22	27.7KB	Share
AGN	Proposed issue of securities - AGN		03/06/22	28.62KB	Share
AGN	Argenica Successfully Completes $5.5m Placement	PRICE SENSITIVE	03/06/22	296.62KB	Share
AGN	Trading Halt	PRICE SENSITIVE	01/06/22	621.25KB	Share
AGN	Successful Completion of Final Pre-Clinical PK Study	PRICE SENSITIVE	19/05/22	228.98KB	Share
AGN	GLP Safety Studies Successfully Completed	PRICE SENSITIVE	05/05/22	223.97KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	541.52KB	Share
AGN	Maximum Tolerated Dose Successfully Established in Studies	PRICE SENSITIVE	26/04/22	213.15KB	Share
AGN	Initial Director's Interest Notice		04/04/22	266.18KB	Share
AGN	Argenica Appoints CEO Dr Liz Dallimore Managing Director	PRICE SENSITIVE	04/04/22	230.49KB	Share
AGN	Positive Preclincal Data on Efficacy in New Indication	PRICE SENSITIVE	30/03/22	502.97KB	Share
AGN	Peer Reviewed Paper Published on Preclinical Study	PRICE SENSITIVE	21/03/22	198.67KB	Share
AGN	Investor Presentation	PRICE SENSITIVE	16/03/22	2.54MB	Share
AGN	Change of Director's Interest Notice		28/02/22	329.95KB	Share
AGN	Successful Completion of Final GLP Genotoxicity Studies	PRICE SENSITIVE	24/02/22	242.32KB	Share
AGN	Half Yearly Report and Accounts	PRICE SENSITIVE	22/02/22	818.74KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/01/22	473.11KB	Share
AGN	Preliminary Pre-Clinical Tox Studies Successfully Completed	PRICE SENSITIVE	24/01/22	259.66KB	Share
AGN	Argenica Appoints Head of Clinical Development		13/01/22	187.08KB	Share
AGN	Notification regarding unquoted securities - AGN		13/01/22	28.43KB	Share
AGN	Application for quotation of securities - AGN		31/12/21	24.23KB	Share
AGN	Application for quotation of securities - AGN		17/12/21	24.25KB	Share
AGN	Release of Restricted Securities from Escrow		10/12/21	190.15KB	Share
AGN	Argenica to be Granted Patent Protection in the US	PRICE SENSITIVE	09/12/21	230.84KB	Share
AGN	Results of Annual General Meeting		17/11/21	240.81KB	Share
AGN	AGM Presentation		17/11/21	2.77MB	Share
AGN	Positive Preclinical Data for ARG-007 Neuroprotection in HIE	PRICE SENSITIVE	03/11/21	601.67KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/21	444.49KB	Share
AGN	Investor Presentation		27/10/21	2.94MB	Share
AGN	Phase 1 Clinical Trial Overview & Roadmap	PRICE SENSITIVE	18/10/21	4.03MB	Share
AGN	Notice of Annual General Meeting/Proxy Form		15/10/21	556.91KB	Share
AGN	Application for quotation of securities - AGN		14/10/21	24.24KB	Share
AGN	Release of Restricted Securities from Escrow		04/10/21	190.44KB	Share
AGN	Argenica Partners With Linear For Phase 1 Clinical Trial	PRICE SENSITIVE	30/09/21	263.09KB	Share
AGN	Date of AGM & Closing Date for Director Nominations		21/09/21	252.21KB	Share
AGN	Argenica Achieves Manufacturing Milestones	PRICE SENSITIVE	14/09/21	414.59KB	Share
AGN	Appendix 4G & Corporate Governance Statement		27/08/21	512.45KB	Share
AGN	Appendix 4E & Annual Report 30 June 2021	PRICE SENSITIVE	27/08/21	1.15MB	Share
AGN	Appendix 3G		11/08/21	382.99KB	Share
AGN	Proposed issue of securities - AGN		05/08/21	25.72KB	Share
AGN	Issue of Options		05/08/21	300.19KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/21	505.58KB	Share
AGN	Grant Secured to Advance Pre-Clinical Studies Of ARG-007	PRICE SENSITIVE	21/07/21	305.39KB	Share
AGN	Study Additional Information	PRICE SENSITIVE	13/07/21	203.18KB	Share
AGN	Study Shows ARG-007 Does Not Degrade	PRICE SENSITIVE	12/07/21	327.58KB	Share
AGN	Argenica Completes Pilot Pre-Clinical Pharmacokinetics Study	PRICE SENSITIVE	01/07/21	249.45KB	Share
AGN	Change of Registered Office		30/06/21	182.32KB	Share
AGN	Investor Presentation		16/06/21	3.29MB	Share
AGN	Argenica Commences Trading on ASX		11/06/21	436.8KB	Share
AGN	Becoming a substantial holder		09/06/21	152.77KB	Share
AGN	Becoming a substantial holder		09/06/21	309.2KB	Share
AGN	Initial Director's Interest Notice x4		09/06/21	268.1KB	Share
AGN	Confirmation Statements		09/06/21	246.09KB	Share
AGN	Top 20 Holders		09/06/21	11.75KB	Share
AGN	Distribution Schedule		09/06/21	9.75KB	Share
AGN	Securities Trading Policy		09/06/21	145.8KB	Share
AGN	Corporate Governance Statement		09/06/21	279.64KB	Share
AGN	Employee Securities Incentive Plan		09/06/21	583.05KB	Share
AGN	Interim Report for the period ended 31 December 2020		09/06/21	559.16KB	Share
AGN	Annual Report for period from incorporation to 30 June 2020		09/06/21	644.64KB	Share
AGN	Constitution		09/06/21	794.21KB	Share
AGN	Prospectus		09/06/21	4.83MB	Share
AGN	Appendix 1A & Information Form and Checklist		09/06/21	350.3KB	Share
AGN	ASX Notice - Admission to Official List		09/06/21	90.16KB	Share
AGN	Supplementary Prospectus		03/05/11	32.04KB	Share
AGN	Anagen Limited Prospectus		15/12/10	4.94MB	Share

AGN Notice of Annual General Meeting/Proxy Form
21/10/22		627.57KB	Share
AGN Investor Presentation
20/10/22		2.7MB	Share
AGN First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007
17/10/22	PRICE SENSITIVE	190.48KB	Share
AGN Argenica Receives $1.38m R&D Tax Incentive Cash Refund
04/10/22	PRICE SENSITIVE	171.67KB	Share
AGN Further Positive Preclinical Results for ARG-007 In HIE
29/09/22	PRICE SENSITIVE	486.34KB	Share
AGN Date of AGM and Closing Date for Director Nominations
16/09/22		186.81KB	Share
AGN Phase 1 Clinical Trial Summary
08/09/22		202.58KB	Share
AGN Argenica Receives Ethics Approval To Commence Phase 1 Trial
07/09/22	PRICE SENSITIVE	229.38KB	Share
AGN Appendix 4G & Corporate Governance Statement
23/08/22		508.22KB	Share
AGN Appendix 4E & Annual Report 30 June 2022
23/08/22	PRICE SENSITIVE	1.31MB	Share
AGN Ethics Application Submitted for Phase 1 Trial
11/08/22		218.25KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	453.67KB	Share
AGN Clinical Advisory Committee Appointment
11/07/22		190.38KB	Share
AGN Notification regarding unquoted securities - AGN
11/07/22		28.11KB	Share
AGN Peer Reviewed Paper Published on Preclinical Safety Study
07/07/22	PRICE SENSITIVE	212.52KB	Share
AGN Investor Presentation - Updated
17/06/22		3.41MB	Share
AGN Change of Director's Interest Notice x2
16/06/22		313.37KB	Share
AGN Investor Presentation
14/06/22		3.34MB	Share
AGN Notification regarding unquoted securities - AGN
10/06/22		383.34KB	Share
AGN Cleansing Notice
10/06/22		172.3KB	Share
AGN Application for quotation of securities - AGN
10/06/22		24.82KB	Share
AGN Proposed issue of securities - AGN
03/06/22		27.7KB	Share
AGN Proposed issue of securities - AGN
03/06/22		28.62KB	Share
AGN Argenica Successfully Completes $5.5m Placement
03/06/22	PRICE SENSITIVE	296.62KB	Share
AGN Trading Halt
01/06/22	PRICE SENSITIVE	621.25KB	Share
AGN Successful Completion of Final Pre-Clinical PK Study
19/05/22	PRICE SENSITIVE	228.98KB	Share
AGN GLP Safety Studies Successfully Completed
05/05/22	PRICE SENSITIVE	223.97KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	541.52KB	Share
AGN Maximum Tolerated Dose Successfully Established in Studies
26/04/22	PRICE SENSITIVE	213.15KB	Share
AGN Initial Director's Interest Notice
04/04/22		266.18KB	Share
AGN Argenica Appoints CEO Dr Liz Dallimore Managing Director
04/04/22	PRICE SENSITIVE	230.49KB	Share
AGN Positive Preclincal Data on Efficacy in New Indication
30/03/22	PRICE SENSITIVE	502.97KB	Share
AGN Peer Reviewed Paper Published on Preclinical Study
21/03/22	PRICE SENSITIVE	198.67KB	Share
AGN Investor Presentation
16/03/22	PRICE SENSITIVE	2.54MB	Share
AGN Change of Director's Interest Notice
28/02/22		329.95KB	Share
AGN Successful Completion of Final GLP Genotoxicity Studies
24/02/22	PRICE SENSITIVE	242.32KB	Share
AGN Half Yearly Report and Accounts
22/02/22	PRICE SENSITIVE	818.74KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
27/01/22	PRICE SENSITIVE	473.11KB	Share
AGN Preliminary Pre-Clinical Tox Studies Successfully Completed
24/01/22	PRICE SENSITIVE	259.66KB	Share
AGN Argenica Appoints Head of Clinical Development
13/01/22		187.08KB	Share
AGN Notification regarding unquoted securities - AGN
13/01/22		28.43KB	Share
AGN Application for quotation of securities - AGN
31/12/21		24.23KB	Share
AGN Application for quotation of securities - AGN
17/12/21		24.25KB	Share
AGN Release of Restricted Securities from Escrow
10/12/21		190.15KB	Share
AGN Argenica to be Granted Patent Protection in the US
09/12/21	PRICE SENSITIVE	230.84KB	Share
AGN Results of Annual General Meeting
17/11/21		240.81KB	Share
AGN AGM Presentation
17/11/21		2.77MB	Share
AGN Positive Preclinical Data for ARG-007 Neuroprotection in HIE
03/11/21	PRICE SENSITIVE	601.67KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
28/10/21	PRICE SENSITIVE	444.49KB	Share
AGN Investor Presentation
27/10/21		2.94MB	Share
AGN Phase 1 Clinical Trial Overview & Roadmap
18/10/21	PRICE SENSITIVE	4.03MB	Share
AGN Notice of Annual General Meeting/Proxy Form
15/10/21		556.91KB	Share
AGN Application for quotation of securities - AGN
14/10/21		24.24KB	Share
AGN Release of Restricted Securities from Escrow
04/10/21		190.44KB	Share
AGN Argenica Partners With Linear For Phase 1 Clinical Trial
30/09/21	PRICE SENSITIVE	263.09KB	Share
AGN Date of AGM & Closing Date for Director Nominations
21/09/21		252.21KB	Share
AGN Argenica Achieves Manufacturing Milestones
14/09/21	PRICE SENSITIVE	414.59KB	Share
AGN Appendix 4G & Corporate Governance Statement
27/08/21		512.45KB	Share
AGN Appendix 4E & Annual Report 30 June 2021
27/08/21	PRICE SENSITIVE	1.15MB	Share
AGN Appendix 3G
11/08/21		382.99KB	Share
AGN Proposed issue of securities - AGN
05/08/21		25.72KB	Share
AGN Issue of Options
05/08/21		300.19KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
29/07/21	PRICE SENSITIVE	505.58KB	Share
AGN Grant Secured to Advance Pre-Clinical Studies Of ARG-007
21/07/21	PRICE SENSITIVE	305.39KB	Share
AGN Study Additional Information
13/07/21	PRICE SENSITIVE	203.18KB	Share
AGN Study Shows ARG-007 Does Not Degrade
12/07/21	PRICE SENSITIVE	327.58KB	Share
AGN Argenica Completes Pilot Pre-Clinical Pharmacokinetics Study
01/07/21	PRICE SENSITIVE	249.45KB	Share
AGN Change of Registered Office
30/06/21		182.32KB	Share
AGN Investor Presentation
16/06/21		3.29MB	Share
AGN Argenica Commences Trading on ASX
11/06/21		436.8KB	Share
AGN Becoming a substantial holder
09/06/21		152.77KB	Share
AGN Becoming a substantial holder
09/06/21		309.2KB	Share
AGN Initial Director's Interest Notice x4
09/06/21		268.1KB	Share
AGN Confirmation Statements
09/06/21		246.09KB	Share
AGN Top 20 Holders
09/06/21		11.75KB	Share
AGN Distribution Schedule
09/06/21		9.75KB	Share
AGN Securities Trading Policy
09/06/21		145.8KB	Share
AGN Corporate Governance Statement
09/06/21		279.64KB	Share
AGN Employee Securities Incentive Plan
09/06/21		583.05KB	Share
AGN Interim Report for the period ended 31 December 2020
09/06/21		559.16KB	Share
AGN Annual Report for period from incorporation to 30 June 2020
09/06/21		644.64KB	Share
AGN Constitution
09/06/21		794.21KB	Share
AGN Prospectus
09/06/21		4.83MB	Share
AGN Appendix 1A & Information Form and Checklist
09/06/21		350.3KB	Share
AGN ASX Notice - Admission to Official List
09/06/21		90.16KB	Share
AGN Supplementary Prospectus
03/05/11		32.04KB	Share
AGN Anagen Limited Prospectus
15/12/10		4.94MB	Share

REFRESH

First

(20min delay)
Last 86.0¢		Change 0.025(2.99%)		Mkt cap ! $106.3M

Open	High	Low	Value	Volume
86.0¢	86.0¢	82.5¢	$113.0K	133.6K

Buyers (Bids)

No.	Vol.	Price($)
1	400	82.5¢

Sellers (Offers)

Price($)	Vol.	No.
86.0¢	619	1

View Market Depth

No.	Vol.	Price($)
1	400	0.825
2	2821	0.820
1	5882	0.815
8	68947	0.810
2	18102	0.805

Price($)	Vol.	No.
0.860	619	1
0.870	10000	1
0.885	15100	1
0.890	24022	2
0.900	9783	2

Last trade - 16.10pm 22/07/2024 (20 minute delay)


Last 85.5¢		Change 0.025 ( 2.33 %)
Open	High	Low	Volume
85.0¢	86.0¢	83.0¢	62863
Last updated 15.59pm 22/07/2024 ?

AGN (ASX) Chart

ARGENICA THERAPEUTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available